These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 2680695)

  • 1. Renal functional impairment and sodium retention in liver cirrhosis.
    Gentilini P; Laffi G
    Digestion; 1989; 43(1-2):1-32. PubMed ID: 2680695
    [No Abstract]   [Full Text] [Related]  

  • 2. Pathophysiology of ascites and functional renal failure in cirrhosis.
    Arroyo V; Bernardi M; Epstein M; Henriksen JH; Schrier RW; Rodés J
    J Hepatol; 1988 Apr; 6(2):239-57. PubMed ID: 3045195
    [No Abstract]   [Full Text] [Related]  

  • 3. Renal Function in Cirrhosis: A Critical Review of Available Tools.
    Piano S; Brocca A; Angeli P
    Semin Liver Dis; 2018 Aug; 38(3):230-241. PubMed ID: 30041275
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Therapy of the hepatorenal syndrome].
    Laffi G; Gentilini P
    Minerva Med; 1987 May; 78(10):669-74. PubMed ID: 3295597
    [No Abstract]   [Full Text] [Related]  

  • 5. Effects of lumbar sympathetic block on kidney function in cirrhotic patients with hepatorenal syndrome.
    Solis-Herruzo JA; Duran A; Favela V; Castellano G; Madrid JL; Muñoz-Yagüe MT; Morillas JD; Estenoz J
    J Hepatol; 1987 Oct; 5(2):167-73. PubMed ID: 3693861
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The hepatorenal syndrome.
    Epstein M
    Hosp Pract (Off Ed); 1989 Apr; 24(4):65-76. PubMed ID: 2522459
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Renal dysfunction in cirrhosis: pathophysiology, diagnosis, and management.
    Sourianarayanane A; Thandassery RB
    Minerva Gastroenterol Dietol; 2016 Jun; 62(2):183-96. PubMed ID: 26731680
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advances in the pathogenesis and treatment of type-1 and type-2 hepatorenal syndrome.
    Arroyo V; Terra C; Ginès P
    J Hepatol; 2007 May; 46(5):935-46. PubMed ID: 17391801
    [No Abstract]   [Full Text] [Related]  

  • 9. Diagnosis and management of renal dysfunction in patients with cirrhosis.
    Carrion AF; Radhakrishnan R; Martin P
    Expert Rev Gastroenterol Hepatol; 2020 Jan; 14(1):1-7. PubMed ID: 31868027
    [No Abstract]   [Full Text] [Related]  

  • 10. Current limits and future challenges in the management of renal dysfunction in patients with cirrhosis: report from the International Club of Ascites.
    Angeli P; Sanyal A; Moller S; Alessandria C; Gadano A; Kim R; Sarin SK; Bernardi M;
    Liver Int; 2013 Jan; 33(1):16-23. PubMed ID: 22507181
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatorenal syndrome. Studies of the effect of vascular volume and intraperitoneal pressure on renal and hepatic function.
    Cade R; Wagemaker H; Vogel S; Mars D; Hood-Lewis D; Privette M; Peterson J; Schlein E; Hawkins R; Raulerson D
    Am J Med; 1987 Mar; 82(3):427-38. PubMed ID: 3548346
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatorenal disorders: role of the sympathetic nervous system.
    Henriksen JH; Ring-Larsen H
    Semin Liver Dis; 1994 Feb; 14(1):35-43. PubMed ID: 8016660
    [No Abstract]   [Full Text] [Related]  

  • 13. Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome.
    Wong F; Pantea L; Sniderman K
    Hepatology; 2004 Jul; 40(1):55-64. PubMed ID: 15239086
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Kidney injury in cirrhosis: pathophysiological and therapeutic aspects of hepatorenal syndromes.
    Møller S; Krag A; Bendtsen F
    Liver Int; 2014 Sep; 34(8):1153-63. PubMed ID: 24673771
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Treatment of ascites, hyponatremia and hepatorenal syndrome in liver cirrhosis].
    Ackermann D
    Ther Umsch; 2009 Nov; 66(11):747-51. PubMed ID: 19885792
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Hepatorenal syndrome].
    Brzozowski R
    Pol Arch Med Wewn; 1972 Oct; 49(4):357-71. PubMed ID: 4571818
    [No Abstract]   [Full Text] [Related]  

  • 17. Molecular adsorbent recirculating system is ineffective in the management of type 1 hepatorenal syndrome in patients with cirrhosis with ascites who have failed vasoconstrictor treatment.
    Wong F; Raina N; Richardson R
    Gut; 2010 Mar; 59(3):381-6. PubMed ID: 19710033
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pathogenetic factors and clinical elements in ascites and hepatorenal syndrome during liver cirrhosis.
    Gentilini P; Laffi G; La Villa G; Raggi VC
    Ann Ital Med Int; 1999; 14(4):264-84. PubMed ID: 10638019
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The growing evidence that renal function should be improved in patients with cirrhosis and hepatorenal syndrome before liver transplantation.
    Moreau R
    J Hepatol; 2004 Jan; 40(1):159-61. PubMed ID: 14672628
    [No Abstract]   [Full Text] [Related]  

  • 20. Ascites and hepatorenal syndrome: pathogenesis and treatment strategies.
    Ginès P; Arroyo V; Rodés J
    Adv Intern Med; 1998; 43():99-142. PubMed ID: 9506180
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.